Drug Trial Radar · NCT04010448
A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and India
Last checked: Nov 20, 2026Latest source record: Apr 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
8,200
Planned (sponsor's estimate)
Start
Oct 10, 2019
Primary completion
Dec 15, 2025
Study completion Dec 15, 2025
Sponsor
- Lead sponsor
- PATHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bill and Melinda Gates Foundation; SK Bioscience Co., Ltd.
- First posted
- Jul 8, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 weeks, up to 8 weeks
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The trial will be a multinational, randomized, double-blind, double-dummy, endpoint driven, group-sequential, active comparator-controlled study, in which participating infants will be randomized 1:1 to receive either: 1) 90 µg of the TV P2-VP8 vaccine IM plus oral placebo, or 2) Rotarix® per os (PO) plus IM placebo. Participants will receive three doses of TV P2-VP8/placebo IM and two doses of Rotarix®/placebo PO at monthly intervals starting at ≥6 to \<8 weeks of age, administered concomitantly with EPI/UIP vaccines. To maintain the blind, infants allocated to the TV P2-VP8 vaccine arm will receive both TV P2-VP8 IM as well as oral placebo vaccine, and infants allocated to receive Rotarix® will receive both Rotarix® PO and placebo IM. Active surveillance for episodes of gastroenteritis (GE) will be conducted throughout the study, through weekly contact with participants' parents. Unsolicited AEs grade ≥ 2 through 28 days after the last study vaccination will be recorded in the study database, as will data for SAEs (including intussusception) throughout the study.
Conditions
- Rotavirus Infection of Children
Interventions
TV P2-VP8Biological
90 µg of the TV P2-VP8 vaccine IM plus oral placebo administered on study days 1, 29 and 57
RotarixBiological
Rotarix® PO plus IM placebo administered on study days 1, 29 and 57
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of laboratory confirmed cases of severe rotavirus gastroenteritis (SRVGE; any strain)Time frame: For cases with onset at least 2 weeks after 3rd study vaccination and onset at any time after first vaccination; for all events within the first 2 years of life
- Number of serious adverse events (SAEs), including intussusceptionTime frame: Through 28 days after the last dose of study vaccine
- Number of Adverse Events (AEs) > or = to grade 2Time frame: Through 28 days after the last dose of study vaccine
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre for Infectious Disease Research in Zambia (CIDRZ)
Lusaka, Zambia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.